Register for email alerts and news feeds:
This journal | BMJ Group
rss
Archives of Disease in Childhood 1998;78:508-512; doi:10.1136/adc.78.6.508
Copyright © 1998 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health.
Arch Dis Child 1998;78:508-512 ( June )

Neurological outcome of methylmalonic acidaemia

P Nicolaides, J Leonard, R Surtees

Institute of Child Health (UCLMS) and Great Ormond Street Hospital for Children NHS Trust, London WC1, UK

Correspondence to: Dr R A H Surtees, The Wolfson Centre, Mecklenburgh Square, London WC1N 2AP, UK. email: R.Surtees{at}ich.ucl.ac.uk


Accepted 5 January 1998

OBJECTIVE---To assess the long term outcome of patients with methylmalonic acidaemia in a cross sectional study.
PATIENTS---All 35 patients with methylmalonic acidaemia seen at Great Ormond Street Hospital for Children in London, UK between 1970 and 1996 were studied. They were divided into cobalamin responsive (n = 6) and non-responsive (n = 29), and early and late onset groups.
RESULTS---There was a significant difference between cobalamin responsive and non-responsive groups in severity, survival, and incidence of neurological sequelae. Cobalamin responsive patients had mild disease, irrespective of age at presentation, their neurological complications were less severe, and they are all alive. The cobalamin non-responsive group comprised 19 early and nine late onset patients. The early onset patients had more severe disease at presentation and 14 have died; all late onset patients are alive. There was no significant difference in abnormal neurological signs, although early onset patients had a significantly reduced full scale intelligence quotient and poor cognitive outcome. In both groups, abnormal neurological signs continue to increase with age.
CONCLUSIONS---Cobalamin responsive patients have a better long term outcome. The outcome in the non-responsive patients, particularly the early onset group, remains poor and alternative treatments should therefore be considered early in this group.

Key messages

  • Survival and neurological outcome in methylmalonic acidaemia is determined by the biochemical response to pharmacological doses of cobalamin and the age of onset of symptoms.
  • Early onset, cobalamin non-responsive patients have greater disease severity, a median survival of six years, and a poorer neurological and cognitive outcome.
  • Cobalamin non-responsive patients have an increased risk of developing new neurological symptoms and signs with age; these develop following episodes of acute metabolic decompensation.



Keywords: methylmalonic acidaemia; cobalamin


© 1998 by Archives of Disease in Childhood

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Chandler, R. J., Zerfas, P. M., Shanske, S., Sloan, J., Hoffmann, V., DiMauro, S., Venditti, C. P. (2009). Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J. 23: 1252-1261 [Abstract] [Full Text]  
  • Trinh, B.-C., Melhem, E. R., Barker, P. B. (2001). Multi-slice Proton MR Spectroscopy and Diffusion-weighted Imaging in Methylmalonic Acidemia: Report of Two Cases and Review of the Literature. Am. J. Neuroradiol. 22: 831-833 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Latest from ADC

 

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics

BMJ Careers - Latest Paediatrics and Paediatric Surgery Jobs

Paediatrics and Paediatric Surgery Jobs